Jim Simons’s Cartesian Therapeutics RNAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $414K | Buy |
67,300
+26,200
| +64% | +$187K | ﹤0.01% | 2676 |
|
|
2025
Q4 | $296K | Buy |
+41,100
| New | +$332K | ﹤0.01% | 2769 |
|
|
2025
Q3 | – | Sell |
-19,500
| Closed | -$203K | – | 3841 |
|
|
2025
Q2 | $203K | Buy |
+19,500
| New | +$208K | ﹤0.01% | 3169 |
|
|
2025
Q1 | – | Sell |
-13,800
| Closed | -$247K | – | 3776 |
|
|
2024
Q4 | $247K | Buy |
+13,800
| New | +$279K | ﹤0.01% | 3101 |
|
|
2024
Q3 | – | Sell |
-17,052
| Closed | -$461K | – | 3824 |
|
|
2024
Q2 | $461K | Sell |
17,052
-1,401
| -8% | -$33.4K | ﹤0.01% | 2730 |
|
|
2024
Q1 | $360K | Buy |
18,453
+1,193
| +7% | +$25.3K | ﹤0.01% | 3006 |
|
|
2023
Q4 | $357K | Sell |
17,260
-6,940
| -29% | -$207K | ﹤0.01% | 2913 |
|
|
2023
Q3 | $770K | Sell |
24,200
-9,217
| -28% | -$308K | ﹤0.01% | 2471 |
|
|
2023
Q2 | $1.12M | Sell |
33,417
-2,353
| -7% | -$84.2K | ﹤0.01% | 2395 |
|
|
2023
Q1 | $1.49M | Sell |
35,770
-5,059
| -12% | -$238K | ﹤0.01% | 2210 |
|
|
2022
Q4 | $1.38M | Buy |
40,829
+10,659
| +35% | +$453K | ﹤0.01% | 2325 |
|
|
2022
Q3 | $1.48M | Buy |
30,170
+10,557
| +54% | +$580K | ﹤0.01% | 2239 |
|
|
2022
Q2 | $771K | Sell |
19,613
-30,067
| -61% | -$891K | ﹤0.01% | 2877 |
|
|
2022
Q1 | $1.83M | Buy |
49,680
+33,807
| +213% | +$2.11M | ﹤0.01% | 2292 |
|
|
2021
Q4 | $1.55M | Buy |
15,873
+7,133
| +82% | +$767K | ﹤0.01% | 2350 |
|
|
2021
Q3 | $1.09M | Sell |
8,740
-5,535
| -39% | -$668K | ﹤0.01% | 2504 |
|
|
2021
Q2 | $1.79M | Buy |
14,275
+4,792
| +51% | +$571K | ﹤0.01% | 2330 |
|
|
2021
Q1 | $1.29M | Sell |
9,483
-22,891
| -71% | -$2.84M | ﹤0.01% | 2489 |
|
|
2020
Q4 | $2.94M | Buy |
32,374
+15,829
| +96% | +$1.37M | ﹤0.01% | 1906 |
|
|
2020
Q3 | $1.23M | Sell |
16,545
-21,360
| -56% | -$1.64M | ﹤0.01% | 2401 |
|
|
2020
Q2 | $3.23M | Sell |
37,905
-11,258
| -23% | -$1.02M | ﹤0.01% | 1894 |
|
|
2020
Q1 | $3.55M | Buy |
49,163
+20,021
| +69% | +$1.93M | ﹤0.01% | 1758 |
|
|
2019
Q4 | $2.08M | Buy |
29,142
+7,996
| +38% | +$386K | ﹤0.01% | 2307 |
|
|
2019
Q3 | $1.11M | Buy |
21,146
+5,429
| +35% | +$289K | ﹤0.01% | 2554 |
|
|
2019
Q2 | $844K | Buy |
15,717
+7,794
| +98% | +$531K | ﹤0.01% | 2768 |
|
|
2019
Q1 | $563K | Buy |
7,923
+4,200
| +113% | +$266K | ﹤0.01% | 2889 |
|
|
2018
Q4 | $297K | Buy |
3,723
+3,303
| +786% | +$754K | ﹤0.01% | 3027 |
|
|
2018
Q3 | $196K | Buy |
+420
| New | +$169K | ﹤0.01% | 3158 |
|
Other funds holding RNAC
VCM
6CM
EAM
Jim Simons's RNAC Position: Q1 2026 in Review
Jim Simons increased its Cartesian Therapeutics (RNAC) stake by 64% in Q1 2026, buying an estimated $187K and bringing the position to 67,300 shares worth $414K. The position accounts for ﹤0.01% of the portfolio, ranked #2676.
Jim Simons first reported a position in RNAC in Q3 2018 and has held it in 28 quarters since. The position peaked at $3.55M in Q1 2020. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.
- Jim Simons held 67,300 shares of Cartesian Therapeutics worth $414K as of Q1 2026.
- Jim Simons bought 26,200 Cartesian Therapeutics shares in Q1 2026, an estimated $187K.
- Cartesian Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2676 holding.
- Jim Simons first reported a position in Cartesian Therapeutics in Q3 2018 and has held it in 28 quarters since.
- Jim Simons's Cartesian Therapeutics position peaked at $3.55M in Q1 2020.
- 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.